A Phase 1 interventional study of Risankizumab and Cytochrome P450 (CYP) Substrates in Ulcerative Colitis (UC) and Crohn's Disease, sponsored by AbbVie. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-07-01.
Sponsored by AbbVie · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 53 studies in Colitis, Ulcerative by AbbVie — 6 open to participants now, 13 under way, 5 of them phase 3. Colitis, Ulcerative · AbbVie.
Among the 53 studies in Colitis, Ulcerative by AbbVie, this one is the 29th largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2020, is one of 4 in phase 1, and was the 33rd registered.
1,854 studies on the registry are indexed under Colitis, Ulcerative; 473 are open to participants now.
Browse Colitis, Ulcerative studies →6 of the 53 studies in Colitis, Ulcerative by AbbVie are open now, in 12 countries. Recruiting first, the newest first:
AbbVie · Sites in United States, Canada, Israel and 2 more countries
Ages 18–75
AbbVie · Sites in Japan
Ages 15+
AbbVie · Sites in United States, Belgium, Brazil and 13 more countries
Ages 2–17
AbbVie · Sites in China
Ages 18+
AbbVie · Sites in Germany
Ages 18+
By country, each count listing its studies:
Of the 307 Colitis, Ulcerative studies recruiting now, 134 (44%) set no upper age limit and 136 (44%) stop at 75 or younger; 71 take children under 18; 41 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 7 · Phase 3 21 · Phase 4 1
First in 2000; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 70 across 1,237 interventional studies indexed under Colitis, Ulcerative.
Median enrollment 156 across the 31 interventional studies, 200 across the 20 observational. Of the 36 that completed or were terminated, 22 (61%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
5 of the studies in Colitis, Ulcerative by AbbVie that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03006068Phase 3AbbVieA Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC) | 2027-07 |
| NCT06880744Phase 3AbbVieA Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab | 2027-08 |
| NCT06838845AbbVieAn Observational Study to Evaluate Effectiveness and Safety of Upadacitinib in Chinese Adult Participants With Moderate to Severely Active Ulcerative Colitis (UC) | 2026-12 |
| NCT05496348AbbVieStudy of Oral Upadacitinib to Assess Change in Disease Activity in Adult Participants With Ulcerative Colitis | 2027-08 |
| NCT06257875AbbVieA Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis | 2027-09 |
Add all 5 to your calendar (.ics) → With an account.
Among the 53 studies in Colitis, Ulcerative by AbbVie, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine).Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. CD may cause tiredness, loose stools with or without bleeding, abdominal pain, weight loss, and fever. This study will evaluate the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD.
Risankizumab is an investigational drug being developed to treat trial participants with inflammatory diseases such as UC and CD. The study is split into two periods. In Period 1, participants will receive single oral doses of CYP sensitive probes and in Period 2, participants will receive risankizumab followed by single oral doses of CYP sensitive probes. Around 20 adult participants with moderately to severely active CD or UC will be enrolled in the study across multiple sites worldwide.
In Period 1, participants will receive oral doses of CYP sensitive probes on Day 1. In Period 2, participants will receive risankizumab by intravenous (IV) infusion on Days 1, 29 and 57 followed by oral CYP sensitive probes on Day 64.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the course of the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests and checking for side effects.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
In Period 1, participants will receive single oral dose of Cytochrome P450 (CYP) substrates on Day 1. In Period 2, three IV doses of risankizumab on Days 1, 29 and 57, followed by single oral dose of CYP substrates on Day 64 will be administered.
Drug: Risankizumab · Drug: Cytochrome P450 (CYP) Substrates
Intravenous (IV) infusion
Also known as: SKYRIZI, ABBV-066
Tablet: Oral; CYP Substrates: midazolam, caffeine, warfarin, vitamin K, omeprazole and metoprolol
Maximum Observed Plasma Concentration (Cmax) of Midazolam
Maximum observed plasma concentration (Cmax) of Midazolam
Time frame: Up to 71 Days
Time to Maximum Observed Plasma Concentration (Tmax) of Midazolam
Time to maximum plasma concentration (Tmax) of Midazolam
Time frame: Up to 71 Days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Midazolam
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Time frame: Up to 71 Days
AUC From Time 0 to Infinity (AUCinf) of Midazolam
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Time frame: Up to 71 Days
Terminal Phase Elimination Rate Constant (β) of Midazolam
Terminal phase elimination rate constant (β) for Midazolam
Time frame: Up to 71 Days
Terminal Phase Elimination Half-Life (t1/2) of Midazolam
Terminal phase elimination half-life (t1/2) of Midazolam
Time frame: Up to 71 Days
Maximum Observed Plasma Concentration (Cmax) of Caffeine
Maximum observed plasma concentration (Cmax) of Caffeine
Time frame: Up to 71 Days
Time to Maximum Observed Plasma Concentration (Tmax) of Caffeine
Time to maximum plasma concentration (Tmax) of Caffeine
Time frame: Up to 71 Days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Caffeine
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Time frame: Up to 71 Days
AUC From Time 0 to Infinity (AUCinf) of Caffeine
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Time frame: Up to 71 Days
Terminal Phase Elimination Rate Constant (β) of Caffeine
Terminal phase elimination rate constant (β) for Caffeine
Time frame: Up to 71 Days
Terminal Phase Elimination Half-Life (t1/2) of Caffeine
Terminal phase elimination half-life (t1/2) of Caffeine
Time frame: Up to 71 Days
Maximum Observed Plasma Concentration (Cmax) of Warfarin
Maximum observed plasma concentration (Cmax) of Warfarin
Time frame: Up to 71 Days
Time to Maximum Observed Plasma Concentration (Tmax) of Warfarin
Time to maximum plasma concentration (Tmax) of Warfarin
Time frame: Up to 71 Days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Warfarin
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Time frame: Up to 71 Days
AUC From Time 0 to Infinity (AUCinf) of Warfarin
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Time frame: Up to 71 Days
Terminal Phase Elimination Rate Constant (β) of Warfarin
Terminal phase elimination rate constant (β) for Warfarin
Time frame: Up to 71 Days
Terminal Phase Elimination Half-Life (t1/2) of Warfarin
Terminal phase elimination half-life (t1/2) of Warfarin
Time frame: Up to 71 Days
Maximum Observed Plasma Concentration (Cmax) of Omeprazole
Maximum observed plasma concentration (Cmax) of Omeprazole
Time frame: Up to 71 Days
Time to Maximum Observed Plasma Concentration (Tmax) of Omeprazole
Time to maximum plasma concentration (Tmax) of Omeprazole
Time frame: Up to 71 Days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Omeprazole
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Time frame: Up to 71 Days
AUC From Time 0 to Infinity (AUCinf) of Omeprazole
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Time frame: Up to 71 Days
Terminal Phase Elimination Rate Constant (β) of Omeprazole
Terminal phase elimination rate constant (β) for Omeprazole
Time frame: Up to 71 Days
Terminal Phase Elimination Half-Life (t1/2) of Omeprazole
Terminal phase elimination half-life (t1/2) of Omeprazole
Time frame: Up to 71 Days
Maximum Observed Plasma Concentration (Cmax) of Metoprolol
Maximum observed plasma concentration (Cmax) of Metoprolol
Time frame: Up to 71 Days
Time to Maximum Observed Plasma Concentration (Tmax) of Metoprolol
Time to maximum plasma concentration (Tmax) of Metoprolol
Time frame: Up to 71 Days
Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Time of the Last Measurable Concentration (AUCt) of Metoprolol
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to time of the last measurable concentration
Time frame: Up to 71 Days
AUC From Time 0 to Infinity (AUCinf) of Metoprolol
Area Under the Plasma Concentration-time Curve (AUC) from time 0 to infinity
Time frame: Up to 71 Days
Terminal Phase Elimination Rate Constant (β) of Metoprolol
Terminal phase elimination rate constant (β) for Metoprolol
Time frame: Up to 71 Days
Terminal Phase Elimination Half-Life (t1/2) of Metoprolol
Terminal phase elimination half-life (t1/2) of Metoprolol
Time frame: Up to 71 Days
Plan to share: No
Ran from May 2020 to primary completion in Oct 2022, 28 months.
Of 58 industry-sponsored phase 1 interventional studies under Colitis, Ulcerative, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 28 months is above that.
Counting every sponsor, half of 84 studies reached it within 13 months; a quarter within 8 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Risankizumab